文献速递慢性肾脏病遗传性与小管间质肾病

基于尿渗透压个体化调整托伐普坦剂量在ADPKD中的前瞻性研究

Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD.
PubMed 文献 · Kidney Int Rep · 2024-01-12

治疗期间OsmU持续低于200 mOsm/kg,多数患者仅需最小剂量(平均64±10 mg),eGFR年下降-3.05±2.41 ml/min/1.73 m2,较治疗前下降幅度减少超过50%,主要肾脏事件发生率20%。

要点

  • 以OsmU<200 mOsm/kg为目标调整托伐普坦剂量,多数患者仅需最小剂量。
  • 治疗期间eGFR年下降-3.05 ml/min/1.73 m2,较治疗前下降幅度减少超过50%。
  • 停药率低(5%),主要肾脏事件发生率20%,平均发生时间31个月。

核心结论

  • 基于OsmU个体化调整托伐普坦剂量可减少快速进展ADPKD患者的eGFR下降,并显示较低停药率和较少副作用。

主要发现

  • 研究期间OsmU持续低于200 mOsm/kg,多数患者需要最小托伐普坦剂量(平均剂量64±10 mg)。
  • 治疗期间eGFR年均下降-3.05±2.41 ml/min/1.73 m2,较治疗前下降幅度减少超过50%。
  • 主要肾脏事件(治疗期间eGFR下降25%)发生于20%的患者,平均发生时间31个月(95%CI 28-34)。
  • 停药率为5%。

关键数值与推荐

  • 托伐普坦剂量调整以OsmU 200 mOsm/kg为上限。
  • 主要肾脏事件定义为治疗期间eGFR下降25%。

临床怎么用

  • 对快速进展的ADPKD患者,可考虑以OsmU<200 mOsm/kg为目标个体化调整托伐普坦剂量,多数患者可能仅需最小剂量。

局限性

  • 需进一步研究确认OsmU用于ADPKD患者托伐普坦剂量调整的最佳策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Tolvaptan has been shown to reduce renal volume and delay disease progression in autosomal-dominant polycystic kidney disease (ADPKD). However, no biomarkers are currently available to guide dose adjustment. We aimed to explore the possibility of individualized tolvaptan dose adjustments based on cut-off values for urinary osmolality (OsmU). METHODS: This prospective cohort study included patients with ADPKD, with rapid disease progression. Tolvaptan treatment was initiated at a dose of 45/15 mg and increased based on OsmU, with a limit set at 200 mOsm/kg. Primary renal events (25% decrease in estimated glomerular filtration rate [eGFR] during treatment), within-patient eGFR slope, and side effects were monitored during the 3-year follow-up. RESULTS: Forty patients participated in the study. OsmU remained below 200 mOsm/kg throughout the study period, and most patients required the minimum tolvaptan dose (mean dose, 64 [±10] mg), with a low discontinuation rate (5%). The mean annual decline in eGFR was -3.05 (±2.41) ml/min per 1.73 m2 during tolvaptan treatment, compared to the period preceding treatment, corresponding to a reduction in eGFR decline of more than 50%. Primary renal events occurred in 20% of patients (mean time to onset, 31 months; 95% confidence interval [CI] = 28-34). CONCLUSION: Individualized tolvaptan dose adjustment based on OsmU in patients with ADPKD and rapid disease progression provided benefits in terms of reducing eGFR decline, compared with reference studies, and displayed lower dropout rates and fewer side effects. Further studies are required to confirm optimal strategies for the use of OsmU for tolvaptan dose adjustment in patients with ADPKD.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Roca Oporto FJ, Andrades Gómez C, Montilla Cosano G, et al. Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD. Kidney Int Rep. 2024. PMID: 38765583. doi:10.1016/j.ekir.2024.01.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。